Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey

Document Type : Original Article


1 Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan

2 Division of Molecular Imaging, Institute of Biomedical Research and Innovation, Kobe, Japan

3 Atsuchi Memorial Institute of Radiology, Atsuchi Memorial Clinic PET Center, Kagoshima, Japan

4 Division of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

5 Department of Radiology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan


Objective(s): The aim of this study was to analyze detection rates and effectiveness of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program for prostate cancer in Japan, which is defined as a cancer-screening program for subjects without known cancer. It contains FDG-PET aimed at detection of cancer at an early stage with or without additional screening tests such as prostate-specific antigen (PSA) and magnetic resonance imaging (MRI).
Methods: A total of 92,255 asymptomatic men underwent the FDG-PET cancer screening program. Of these, 504 cases with findings of possible prostate cancer in any screening method were analyzed.
Results: Of the 504 cases, 165 were verified as having prostate cancer. Of these, only 61 cases were detected by FDG-PET, which result in 37.0% relative sensitivity and 32.8% positive predictive value (PPV). The sensitivity of PET/computed tomography (CT) scanner was higher than that of dedicated PET (44.0% vs. 20.4%). However, the sensitivity of FDGPET was lower than that of PSA and pelvic MRI. FDG-PET did not contribute to improving the sensitivity and PPV when performed as combined screening.
Conclusion: PSA should be included in FDG-PET cancer screening programs to screen for prostate cancer.


  1. Foundation for Promotion of Cancer Research: cancer statistics in Japan-2012. [Internet] Available from:
  2. Foundation for Promotion of Cancer Research: cancer stattiatics in Japan-2012. [Internet] Available from:
  3. Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol. 1995; 154: 1085-9.
  4. Ito K, Ichinose Y, Kubota Y, Imai K, Yamanaka H. Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy. Int J Urol. 1997; 4: 474-9.
  5. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151: 1283-90.
  6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-49.
  7. Bartsch G, Horninger W, Klocker H , Reissigl A, Oberaigner W, Schönitzer D, et al. Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001; 58: 417-24.
  8. Oberaigner W, Horninger W, Klocker H, Schönitzer D, Stühlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164: 376-84.
  9. Minamimoto R, Senda M, Jinnouchi S, Terauchi T, Yoshida T, Murano T, et al. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey. Ann Nucl Med.2013; 27:46-57.
  10. The guideline of FDG-PET cancer screening. 2004. [Internet] Available from: http:// 01bunshi/fdg.pdf.
  11. The guideline of FDG-PET cancer screening. Kaku Igaku. 2007;44:1–28.
  12. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007; 51:1511–21.
  13. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52:81-9.
  14. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999; 29: 623–9.
  15. Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2011; 25:21-7.
  16. Wahl RL. Principles and practice of PET and PET/CT. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2009. P. 47–57.
  17. Hwang I, Chong A, Jung SI, Hwang EC, Kim SO, Kang TW, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images?. Ann Nucl Med. 2013; 27:140-5.
  18. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol. 2002; 41: 425-9.
  19. Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996; 155: 994–8.
  20. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007; 243: 28-53.
  21. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection, version 2. 2012. [Internet] Available from: /professionals/physician_gls/pdf/prostate_detection.pdf.
  22. Pinto F, Totaro A, Calarco A, Calarco A, Proietti G, Totaro A, et al. Imaging in prostate cancer diagnosis: present role and future perspectives. Urol Int. 2011; 86: 373-82.